There are 2137 resources available
817P - Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial
Presenter: Adriaan Vanderstichele
Session: E-Poster Display
Resources:
Abstract
804TiP - CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
Presenter: Laurence Albiges
Session: E-Poster Display
Resources:
Abstract
818P - Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study
Presenter: Aikou Okamoto
Session: E-Poster Display
Resources:
Abstract
819P - Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Presenter: Giorgio Valabrega
Session: E-Poster Display
Resources:
Abstract
820P - Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC)
Presenter: Xiaohua Wu
Session: E-Poster Display
Resources:
Abstract
821P - Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study
Presenter: Andrew Dean
Session: E-Poster Display
Resources:
Abstract
823P - Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study
Presenter: Thibault de La Motte Rouge
Session: E-Poster Display
Resources:
Abstract
824P - Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p)
Presenter: Andrea Plaja Salarich
Session: E-Poster Display
Resources:
Abstract
825P - Olaparib maintenance therapy in routine clinical practice: Quality of life interim results of the non-interventional C-PATROL study in ovarian cancer patients in Germany
Presenter: Frederik Marmé
Session: E-Poster Display
Resources:
Abstract
826P - Comparative efficacy of first-line maintenance PARP inhibitors (PARPI) in advanced ovarian cancer (OC): A network meta-analysis
Presenter: Dalia Hammoud
Session: E-Poster Display
Resources:
Abstract